GlassScriptPhysician profile
Darlene B Litton
NPI 1629001862
$998.26
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $356 · 2021: $151.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $276.75 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $113.71 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.31 | 2019-2021 | |
| Pfizer INC. | $99.97 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.96 | 2019 | |
| Esperion Therapeutics, INC. | $45.35 | 2020 | |
| Amarin Pharma, INC. | $43.55 | 2020 | |
| Amgen INC. | $43.43 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $39.09 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $30.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.64 | 2019 | |
| Lilly USA, LLC | $27.45 | 2019-2020 | |
| Abbvie INC. | $23.69 | 2019 | |
| Horizon Therapeutics Plc | $18.43 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.78 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $13.23 | 2021 | |
| Allergan, INC. | $11.36 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darlene Litton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.